<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953507</url>
  </required_header>
  <id_info>
    <org_study_id>AP2104-50104</org_study_id>
    <nct_id>NCT04953507</nct_id>
  </id_info>
  <brief_title>Evaluation of T2, T3 Sympathectomy for Postmastectomy Pain Syndrome by Pulse Oximeter</brief_title>
  <official_title>Evaluation of T2, T3 Sympathectomy for Postmastectomy Pain Syndrome by Thermal Radiofrequency Versus Chemical Neurolysis Using Perfusion Index Derived Pulse Oximeter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the efficacy of T2, T3 sympathetic block using thermal&#xD;
      radiofrequency versus chemical neurolysis in postmastectomy pain syndrome using perfusion&#xD;
      index derived from pulse oximetry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postmastectomy pain is a chronic pain condition with neuropathic nature. Several drugs and&#xD;
      methods are used for its management. This study was designed to compare the efficacy of both&#xD;
      thermal radiofrequency and chemical neurolysis in management of postmastectomy pain through&#xD;
      using perfusion index derived from pulse oximetry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perfusion index trend</measure>
    <time_frame>procedure time</time_frame>
    <description>measuring the change in perfusion index in the ipsilateral limb compared to the control limb</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analogue score</measure>
    <time_frame>6 weeks</time_frame>
    <description>minimum score 0 and maximum score 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>6 weeks</time_frame>
    <description>total opioid consumption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Thermal Radiofrequency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T2, T3 block by thermal radiofrequency lesioning at 80°c for 60-90 seconds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemical Neurolysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>T2, T3 block by chemical neurolysis using 2-3 ml of phenol in glycerin 6%</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thermal Radiofrequency</intervention_name>
    <description>Radiofrequency lesioning at level of T2, T3 using 80°c for 60-90 seconds</description>
    <arm_group_label>Thermal Radiofrequency</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chemical Neurolysis</intervention_name>
    <description>injection of 2 to 3 ml of the chemical neurolytic agent (phenol in glycerin 6%)</description>
    <arm_group_label>Chemical Neurolysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients with postmastectomy pain syndrome&#xD;
&#xD;
          -  ≥ Age 18 years&#xD;
&#xD;
          -  ASA II-III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient refusal&#xD;
&#xD;
          -  coagulation defects&#xD;
&#xD;
          -  abnormal kidney or liver functions&#xD;
&#xD;
          -  local infection at site of injection&#xD;
&#xD;
          -  bone metastases&#xD;
&#xD;
          -  severe cardiorespiratory disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walaa Y Elsabeeny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer of Anesthesia and Pain Management, National Cancer Institute, Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walaa Y Elsabeeny, MD</last_name>
    <phone>01007798466</phone>
    <phone_ext>+2</phone_ext>
    <email>walaa.elsabeeny@nci.cu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Walaa Y Elsabeeny</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walaa Y Elsabeeny, MD</last_name>
      <phone>01007798466</phone>
      <email>walaa.elsabeeny@nci.cu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Walaa Youssef Elsabeeny</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia and Pain management</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be available upon reasonable request through contacting the corresponding author</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

